A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 384
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : EAMG
Long Form : experimental autoimmune myasthenia gravis
No. Year Title Co-occurring Abbreviation
2021 Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients. MG
2021 Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses. AChR, DMARD, MG, PA, RA
2021 Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells. ELISA, S1P
2021 [Rapamycin alleviates the symptoms of experimental autoimmune myasthenia gravis rats by down-regulating Th17 cell/regulatory T cell ratio]. CFA group, Con A, RAPA
2020 AEB-071 Ameliorates Muscle Weakness by Altering Helper T Lymphocytes in an Experimental Autoimmune Myasthenia Gravis Rat Model. AEB, MG
2020 Effect of Grilled Nux Vomica on Differential RNA Expression Profile of Gastrocnemius Muscle and Toll‑Like Receptor 4 (TLR-4)/Nuclear Factor kappa B (NF-κB) Signaling in Experimental Autoimmune Myasthenia Gravis Rats. AChRs, DEGs, ELISA, GNV, MG, NF-kappaB, PPI, TLR4
2020 Osteopontin exacerbates the progression of experimental autoimmune myasthenia gravis by affecting the differentiation of T cell subsets. MG, OPN
2020 Suppression of the CD28/B7 pathway reduces the occurrence and development of myasthenia gravis and cytokine levels. AChR, MG
2020 Unraveling the Role of Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Myasthenia Gravis. AChRs, MG, NMJ, RAGE, Th
10  2019 CXCR5-negative natural killer cells ameliorate experimental autoimmune myasthenia gravis by suppressing follicular helper T cells. NK
11  2019 Enhancement of T Follicular Helper Cell-Mediated Humoral Immunity Reponses During Development of Experimental Autoimmune Myasthenia Gravis. AChR alpha, MG, Tfh
12  2019 Inhibition of ROCK activity regulates the balance of Th1, Th17 and Treg cells in myasthenia gravis. MG, PBMCs
13  2019 Metformin attenuates autoimmune disease of the neuromotor system in animal models of myasthenia gravis. AMPK, MG
14  2019 MiR-181a regulates CD4+ T cell activation and differentiation by targeting IL-2 in the pathogenesis of myasthenia gravis. MG, miRNAs, PBMCs
15  2019 Profiling of patient-specific myocytes identifies altered gene expression in the ophthalmoplegic subphenotype of myasthenia gravis. MG, OP-MG
16  2018 A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire. KI, TAChR, TCR
17  2018 Acetylcholine receptor-specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis. AChRs, MG
18  2018 Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats. EAE, TGF-beta
19  2018 Artemisinin ameliorates the symptoms of experimental autoimmune myasthenia gravis by regulating the balance of TH1 cells, TH17 cells and Treg cells. EAE, MG, MNCs, SLE, TGF-beta1, TNF-alpha
20  2018 Effect of Qiangji Jianli decoction on mitochondrial respiratory chain activity and expression of mitochondrial fusion and fission proteins in myasthenia gravis rats. AChRs, MFF, MG, QJJL, TCM
21  2018 Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats. 2-ME, Abs, AChR, AHR, APC, APCs, CFA, Cy3, DCs, EAE, FBS, FCS, FITC, i.p, IFA, IFN, Ig, IL, IL-9, JAK, MG, MNC, NMJ, OD, OVA, PBS, PE, rr, rrIL-9, RT, STAT, Th
22  2018 Therapeutic potential of artesunate in experimental autoimmune myasthenia gravis by upregulated T regulatory cells and regulation of Th1/Th2 cytokines. MG
23  2018 Toll-like receptor 9 antagonist suppresses humoral immunity in experimental autoimmune myasthenia gravis. DCs, GC, MG, ODN, TLR9
24  2018 Treatment of experimental autoimmune myasthenia gravis rats with FTY720 and its effect on Th1/Th2 cells. AChR, IFN, IL, MG, Th
25  2017 A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146. AChR
26  2017 Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity. MG
27  2017 Caspase-1 inhibitor regulates humoral responses in experimental autoimmune myasthenia gravis via IL-6- dependent inhibiton of STAT3. caspase-1, ELISA, i.p
28  2017 Decreased bone mineral density in experimental myasthenia gravis in C57BL/6 mice. BMD, MG, TAChR
29  2017 Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis. CFA, MuSK, NMJs, PBS, TAChR
30  2017 IFNA-AS1 regulates CD4+ T cell activation in myasthenia gravis though HLA-DRB1. MG, QMG
31  2017 Immature Exosomes Derived from MicroRNA-146a Overexpressing Dendritic Cells Act as Antigen-Specific Therapy for Myasthenia Gravis. DCs, MG
32  2017 Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice. AChR, LRP4, MG, MuSK, NMJ
33  2017 Muscle satellite cells are functionally impaired in myasthenia gravis: consequences on muscle regeneration. AChR, MG, SCs
34  2017 NFAT1 Regulates Systemic Autoimmunity through the Modulation of a Dendritic Cell Property. DC
35  2017 ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response. ---
36  2017 Regulatory T cells in multiple sclerosis and myasthenia gravis. EAE, MG, MS
37  2017 S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset. MG, S1P
38  2016 Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells. MG, RSG
39  2016 Curcumin ameliorates experimental autoimmune myasthenia gravis by diverse immune cells. MG
40  2016 Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway. BMDCs, DCs, Dex, DMSO, IDO, PBS
41  2016 Ginsenoside Rb1: The new treatment measure of myasthenia gravis. G-Rb1, MG, MNCs
42  2016 Impaired regulatory B cells in myasthenia gravis. IL-10
43  2016 MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK. KO, MG, MuSK-Ab, WT
44  2016 ROCK inhibitor abolishes the antibody response in experimental autoimmune myasthenia gravis. ---
45  2016 [Tetramethylpyrazine attenuates experimental autoimmune myasthenia gravis in rats via regulating related cytokines and antibodies]. AChR, IFN-gamma, IL-10, TMP, TNF-alpha
46  2015 A new method to induce myasthenia gravis models and the protective effect of soluble decay accelerating factors. AChR, DAF, ECD, ELISA
47  2015 AChR-specific immunosuppressive therapy of myasthenia gravis. AChRs, MG, MIR
48  2015 Association study between IL-17A and IL-17F gene polymorphism and myasthenia gravis in Chinese patients. ---
49  2015 Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway. caspase-1, MG
50  2015 Deficits in endogenous adenosine formation by ecto-5'-nucleotidase/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis. A2ARs, ADO
51  2015 Dental follicle mesenchymal stem cell administration ameliorates muscle weakness in MuSK-immunized mice. AChR, DFMSC, MG, MSC, MuSK, NMJ
52  2015 Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization. AChR, MG, NMJ
53  2015 IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice. AChR, NMJ, WT
54  2015 IL-10 derived from CD1dhiCD5⁺ B cells regulates experimental autoimmune myasthenia gravis. ---
55  2015 IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis. tAChR
56  2015 Immature dendritic cell exosomes suppress experimental autoimmune myasthenia gravis. BM, iMDEX
57  2015 Low and high doses of ursolic acid ameliorate experimental autoimmune myasthenia gravis through different pathways. MG, UA
58  2015 miR-15b is Downregulated in Myasthenia Gravis Patients and Directly Regulates the Expression of Interleukin-15 (IL-15) in Experimental Myasthenia Gravis Mice. IL-15, MG
59  2015 Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice. AChR, CFA, EOM, H-AChR, HLA, MG
60  2015 Research on the influence of alpha-GalCer activating experimental autoimmune myasthenia gravis mice NKT cells at different times on myasthenia gravis. NKT
61  2015 Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs. AChR, MG
62  2015 Statin-modified dendritic cells regulate humoral immunity in experimental autoimmune myasthenia gravis. AT-BMDCs, DCs
63  2015 Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells. AA, BM, Treg
64  2014 Adenosine receptor expression in a rat model of experimental autoimmune myasthenia gravis. PBMCs
65  2014 Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis. AChRs, MG
66  2014 CD1d(hi)CD5+ B cells expanded by GM-CSF in vivo suppress experimental autoimmune myasthenia gravis. ---
67  2014 Design, synthesis, and characterization of a 39 amino acid peptide mimic of the main immunogenic region of the Torpedo acetylcholine receptor. Abs, IChBD, mAbs, MIR, TAChR
68  2014 Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches. AChR, MG
69  2014 Improved methodology to obtain large quantities of correctly folded recombinant N-terminal extracellular domain of the human muscle acetylcholine receptor for inducing experimental autoimmune myasthenia gravis in rats. AChR, ECD, IPTG, MG, PCR
70  2014 Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis. AChR, MDSCs
71  2014 Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses. IL-9, MG
72  2014 Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice. AChR, CFA, Ig, LRP4, MG, MuSK
73  2014 Protective effect of Sijunzi decoction on neuromuscular junction ultrastructure in autoimmune myasthenia gravis rats. ATP, NMJ
74  2014 RNA expression analysis of passive transfer myasthenia supports extraocular muscle as a unique immunological environment. AChR, EDL, EOM
75  2014 Role of ubiquitin ligase Cbl-b in B-cell activation of dendritic cells loaded with Talpha146-162 in the treatment of experimental autoimmune myasthenia gravis in mice. PLC
76  2014 The decreased expression of thioredoxin-1 in brain of mice with experimental autoimmune myasthenia gravis. AChR, CHOP, CREB, MDA, MG, Trx-1
77  2014 Tissue plasminogen activator involvement in experimental autoimmune myasthenia gravis: aggravation and therapeutic potential. tPA
78  2013 Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines. DCs, MG, MNC, p.i, Treg
79  2013 ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh/Tfr helper cell profiles. AChR, ATRA, MG
80  2013 Complement associated pathogenic mechanisms in myasthenia gravis. Ab, AChR, DAF, KO, MAC, MG, NMJ
81  2013 Complement C2 siRNA mediated therapy of myasthenia gravis in mice. ---
82  2013 Experimental autoimmune myasthenia gravis in the mouse. AChR, MG
83  2013 Experimental myasthenia gravis in Aire-deficient mice: a link between Aire and regulatory T cells. reg, WT
84  2013 Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK+) experimental autoimmune Myasthenia gravis (EAMG). MG, TA
85  2013 Prophylactic effect of probiotics on the development of experimental autoimmune myasthenia gravis. AChR, MG, rDCs
86  2013 Proteomic analysis of rat tibialis anterior muscles at different stages of experimental autoimmune myasthenia gravis. AChR, MG
87  2013 RNA interference targeting Bcl-6 ameliorates experimental autoimmune myasthenia gravis in mice. BCL6, RNAi, shRNAs
88  2013 Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor. AChR, mAbs, MG, MIR
89  2012 Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity. A2AR, AChR
90  2012 Cell surface complement regulators moderate experimental myasthenia gravis pathology. AChR, NMJ
91  2012 Changes in acetylcholinesterase in experimental autoimmune myasthenia gravis and in response to treatment with a specific antisense. AChE, AChRs, EDL, NMJ
92  2012 Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis. AChR, MG, NMJ
93  2012 DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis. RCA
94  2012 Novel animal models of acetylcholine receptor antibody-related myasthenia gravis. AChR, KO, MG, WT
95  2012 The role of complement in experimental autoimmune myasthenia gravis. ---
96  2011 Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. Th17
97  2011 Characterization of peripheral blood acetylcholine receptor-binding B cells in experimental myasthenia gravis. Abs, AChR, MG
98  2011 Complement and cytokine based therapeutic strategies in myasthenia gravis. AChR, MG
99  2011 Experimental autoimmune myasthenia gravis in the mouse. AChR, MG
100  2011 GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. GM-CSF